arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Protalix BioTherapeutics, Inc.

PLX
$2.51 ▼ -0.17 (-6.34%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Protalix BioTherapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $197.2M
Dividend Yield —
Revenue Growth -1.2% ↗
Op. Margin -10.4% ↘
ROIC -13.4% ↘
FCF / Share $-0.17 ↘
Trailing P/E —
Price / Book 4.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$52.74M
↓ -1.2% —
Net Income Profit after all expenses
$-6.60M
↓ -325.2% —
Operating Margin Operating profit as % of sales
-10.4%
↓ -242.2% 15th
FCF / Share Free cash flow per share
$-0.17
↓ -270.3% —
Long-Term Debt Long-term obligations
$912.00K
↓ -61.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
12
Returns
31
Cash Quality ↑
87

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters